➡️ Disseminated on behalf of: TempraMed Technologies Ltd.
__
“130,000 devices have been sold already. Our products have been validated with the likes of Amazon, Walmart, and Walgreens.”
Ron Nagar, Founder and CEO, and Julia Becker, VP of Capital Markets at
@TempraMed_Tech (CSE:
$VIVI | FSE: 9DY), discuss how the company is addressing the temperature protection challenge in the growing $30 billion injectable medication market, with four products in market designed for insulin, EpiPens, GLP-1s, growth hormones, and other temperature-sensitive treatments.
Watch the full video to see how TempraMed is building on its device sales and retail validation to expand toward B2B partnerships, global distribution, and broader digital health applications.